Centessa Pharmaceuticals Limited (CNTA) is a bio-pharmaceutical company that focuses on the development and commercialization of innovative therapies. Technical analysis plays a crucial role in understanding the price movement and trend of CNTA's stock. By analyzing various technical indicators, investors can make informed decisions about buying or selling CNTA shares.

One of the most widely used technical indicators is the Relative Strength Index (RSI). This indicator measures the strength and speed of a stock's price movement. For CNTA, a high RSI value may indicate that the stock is overbought, while a low RSI value may suggest that the stock is oversold. Traders often use this information to determine potential entry or exit points.

Centessa Pharmaceuticals Limited (CNTA) Technical Analysis

Learn about the technical indicators for Centessa Pharmaceuticals Limited (CNTA) stock, including RSI, ADX, and MACD. Analyze Centessa Pharmaceuticals Limited (CNTA) stock ROC, STOCHRSI, and WILLR. Rating and analysis provided.

Centessa Pharmaceuticals Limited (CNTA) Technical Analysis: RSI, ADX, MACD

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Centessa Pharmaceuticals Limited

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	62.40	Neutral	2.2%
auto_graphMACD	1,016.27	Neutral	63.6%
auto_graphCCI	56.38	Neutral	123.8%
auto_graphADX	49.36	Neutral	-
auto_graphATR	730.92	Buy	-
auto_graphWILLR	-32.68	Neutral	80.4%
auto_graphROC	11.64	Neutral	62.0%
auto_graphSTOCHRSI	0.00	Buy	21.0%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Centessa Pharmaceuticals Limited (CNTA) Technical Analysis

Keep an eye on Centessa Pharmaceuticals Limited

Frequently Asked Questions

What are the technical signals for Centessa Pharmaceuticals Limited (CNTA) stock based on the last 30 days?

Take Your Investments to a Whole New Level